STATEMENT

Biopharmaceutical CEO Roundtable meets in New York, focusing on global health and pharmaceutical innovation

The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in New York on 28 November 2023, to discuss global health challenges and public health policies impacting biomedical innovation.

1 DECEMBER 2023, NEW YORK CITY - The CEOs of leading biopharmaceutical companies met to focus on global health challenges and the importance of pharmaceutical innovation to the health and economic security of countries around the world.

The meeting included discussion on how the industry can use its expertise to address the biggest global health challenges and achieve health equity. Fostering a sustainable global innovation ecosystem supported by the intellectual property framework emerged as a key focal point during discussions.

The conversations took place as the world looks to strengthen the global architecture for pandemic preparedness and response, taking stock of lessons learned from the collective response to COVID-19.

IFPMA President and BCR Chair Dr. Albert Bourla, Chairman and CEO of Pfizer:

“The biopharmaceutical industry is committed to being a partner in tackling the world’s biggest health and economic challenges, and today’s meeting reflects that ambition.

“In response to the COVID-19 pandemic, we saw science and innovation deliver. It is essential that we have the right frameworks in place to ensure that it can deliver again – whether that is to fight the next pandemic, to tackle the rise of antimicrobial resistance, or to deliver the next generation of medicines to treat patients worldwide.”

IFPMA Director General and Secretary of BCR, Thomas Cueni:

“Our industry is steadfast in its commitment to deliver better health. But delivering on our shared ambition to tackle the most pressing global health challenges will require collaboration and open ears on all sides. This also hinges on a better understanding of what makes progress against disease possible – a thriving innovation ecosystem that allows science to discover new medicines and vaccines, but also the need to invest more and better in the healthcare infrastructure and delivery systems. The BCR meeting in New York provided a very important opportunity to bring these discussions to the fore.”
About the Biopharmaceutical CEO Roundtable (BCR)
The BCR is a global policy forum where the CEOs of International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) member companies discuss global health policies impacting biomedical innovation. Where possible, the BCR organizes meetings with government officials and policymakers.

About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.

For further information, please contact:
Elliot Dunster
Executive Director, Communications, IFPMA
+41 79 502 76 90
E.dunster@ifpma.org